Welcome to our dedicated page for Vor Biopharma news (Ticker: VOR), a resource for investors and traders seeking the latest updates and insights on Vor Biopharma stock.
Vor Biopharma Inc. (Vor Bio) (Nasdaq: VOR) is a clinical-stage biotechnology company focused on transforming the treatment of autoimmune diseases through the development of telitacicept, a dual BAFF/APRIL fusion protein. The VOR news page on Stock Titan aggregates company press releases and third-party coverage so readers can follow how Vor Bio’s telitacicept program and corporate strategy evolve over time.
According to recent announcements, Vor Bio’s news flow centers on late-stage clinical data for telitacicept in B‑cell–mediated autoimmune diseases, including generalized myasthenia gravis, Sjögren’s disease, systemic lupus erythematosus, and IgA nephropathy. The company and its collaborator RemeGen Co., Ltd. have reported Phase 3 results from studies conducted in China, including data presented at major medical meetings and in peer‑reviewed publications. These updates highlight efficacy endpoints, durability of response, and safety findings for telitacicept across multiple indications.
Investors following VOR news can also track capital markets activity, such as underwritten public offerings, private placements with institutional healthcare investors, and at‑the‑market equity sales programs disclosed in company press releases and Form 8‑K filings. Additional news items cover leadership and governance changes, including appointments to the Board of Directors and executive team roles like Chief Medical Officer, Chief Development Officer, and Chief Commercial Officer, which Vor Bio links to its late-stage development and potential commercialization plans.
Vor Bio’s participation in healthcare and investor conferences, including events such as the J.P. Morgan Healthcare Conference and other sector-focused meetings, is another recurring news theme. Visitors to this page can review updates on upcoming presentations, webcasts, and corporate slide decks referenced in SEC filings. For anyone monitoring VOR, the news feed offers a centralized view of clinical milestones, financing decisions, and strategic developments related to telitacicept and Vor Bio’s broader autoimmune disease focus.
Vor Biopharma (Nasdaq: VOR) and Abound Bio have entered a strategic collaboration to develop CAR-T treatments combined with Vor's engineered hematopoietic stem cell (eHSC) platform, focused on treating acute myeloid leukemia (AML) and other blood cancers. The partnership aims to enhance multi-targeted CAR-T therapies while protecting healthy cells, aligning with Vor's mission of creating effective cancer treatments. Financial terms of the collaboration were not disclosed.
Vor Biopharma, a pioneering cell therapy company, announced that its President, Robert Ang, and CFO, Nathan Jorgensen, will present at two key conferences. The Jefferies Virtual Healthcare Conference is scheduled for June 1, 2021, at 4:00 PM ET, followed by the Goldman Sachs 42nd Annual Global Healthcare Conference on June 9, 2021, at 9:40 AM ET. These presentations will showcase Vor's innovative engineered hematopoietic stem cell therapies aimed at treating cancer. Live webcasts will be available on the company's website.
Vor Biopharma (Nasdaq: VOR) announced the clearance of its clinical trial application (CTA) for VOR33 in acute myeloid leukemia (AML) by Health Canada, marking a significant regulatory milestone. The company successfully raised $203.4 million through its initial public offering (IPO), enhancing its cash position to $262.6 million as of March 31, 2021. In addition, Vor plans to present critical findings regarding VOR33 at the American Society of Gene & Cell Therapy (ASGCT) Annual Meeting, supporting its upcoming Phase 1/2a trial set to begin in Q2 2021.
Vor Biopharma (Nasdaq: VOR) announces two presentations at the American Society of Gene & Cell Therapy (ASGCT) Annual Meeting on May 11, 2021. The presentations will focus on VOR33, an engineered hematopoietic stem cell (eHSC) clinical candidate targeting acute myeloid leukemia. The oral presentation by Dr. John Lydeard will detail the CRISPR/Cas9 technology used in VOR33, while a poster will assess off-target editing. These developments aim to enhance treatment efficacy and patient outcomes.
Vor Biopharma (Nasdaq: VOR) announced that the FDA accepted the IND for VOR33, its lead eHSC product candidate targeting acute myeloid leukemia (AML). The company successfully completed an IPO, raising $203.4 million, enhancing its financial standing. Cash at year-end 2020 was $48.5 million, with R&D expenses rising to $31.6 million due to increased preclinical studies. Vor reported a net loss of $43.3 million for 2020. Upcoming milestones include the initiation of the Phase 1/2a trial for VOR33 in Q2 2021 and initial data expected in late 2021 or early 2022.
Vor Biopharma (Nasdaq: VOR), a leader in engineered hematopoietic stem cell therapies, announced its participation in the Barclays Global Healthcare Conference, set for March 9-11, 2021. CEO Robert Ang and CFO Nathan Jorgensen will present on March 11 at 3:00 p.m. E.T. Interested parties can access the live webcast through the Investors section of Vor's website. Vor Biopharma is dedicated to innovating cancer treatments, focusing on creating treatment-resistant transplants that enhance targeted therapies while protecting healthy cells.
Vor Biopharma (Nasdaq: VOR), a leader in engineered hematopoietic stem cell (eHSC) therapies for cancer treatment, will participate in the Cowen 41st Annual Health Care Conference from March 1-4, 2021. CEO Robert Ang and CFO Nathan Jorgensen are set to present on March 4 at 1:30 p.m. E.T. The company focuses on developing treatment-resistant transplants that enhance the effectiveness of targeted therapies, allowing for the selective destruction of cancer cells while preserving healthy tissue.
Vor Biopharma (Nasdaq: VOR) has successfully closed its initial public offering (IPO), issuing 9,828,017 shares of common stock, with an additional 1,474,202 shares sold due to underwriter options. The shares, priced at $18.00 each, generated gross proceeds of approximately $203.4 million. Trading began on February 5, 2021. This IPO enhances Vor's financial position as it continues to develop engineered hematopoietic stem cell therapies targeting cancer treatment.
PureTech Health announces that its founded entity, Vor Biopharma, has priced its initial public offering (IPO) of 9,828,017 shares at $18.00 each, raising approximately $176.9 million before expenses. The shares are slated to start trading on Nasdaq under the symbol VOR on February 5, 2021, with the offering expected to close by February 9, 2021. Following the IPO, PureTech will hold 3,207,200 shares of Vor, representing about 9.0% of its outstanding shares.
Vor Biopharma (Nasdaq: VOR), a cell therapy firm, announced the pricing of its IPO, offering 9,828,017 shares at $18.00 per share. This will raise approximately $176.9 million before deductions. The underwriters have a 30-day option to purchase an additional 1,474,202 shares. Trading is set to start on February 5, 2021, with the offering closing on February 9, 2021. Goldman Sachs and others are the joint book-running managers. Registration statements have been filed with the SEC.